http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2290973-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcbfbc6b04aa669dab2db93d784a9abf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fb302b4b271201a200dbd4d1a7ab0b2e
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
filingDate 2005-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2007-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e8e19e8a2856230c168044b4df28827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e37803790e4b4d075b377bedaf253e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a8b8b699222b9bf6135db04a192cb98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8581c0f131ce972457a0893f6b8d635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45ed6c2fff048b13ca09c95b7d4ddc9f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4839fd77116732868d16182667f3cf5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7d41f3f07dda1c336dbf2c32261a78d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e32e23f0d64bd8c6e971c3e70b4242c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40c4d872f0739d323edd487023b0b0d6
publicationDate 2007-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2290973-C1
titleOfInvention Method of curing subretinal neovascular membrane
abstract FIELD: ophthalmology. n SUBSTANCE: photodynamic therapy is performed due to intravenous injection of photo-sensitizer followed by radiation. As photo sensitizer the Photosense is used in dosage of 0,05-0,3 mkg/gram per weight. Laser radiation of membrane is carried out trans-papillary three days after Photosense was introduced. Membranes are radiated multiple at wavelength of 675 micron and power density of 80-200 mW/cm 2 . Membranes are subject to radiation every 3-5 days without additional injection of Photosense. Two to ten procedures are taken in total. n EFFECT: reduced frequency of relapses of subretinal neovascular membranes; improved vision functions. n 3 cl, 2 dwg, 2 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2539664-C1
priorityDate 2005-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743345
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426391190
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419569951
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433322774
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419551303
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5416
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5864210
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411295375
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154496932
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535717
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6335806
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426122051
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21159705
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280899
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6918321
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523371
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71308305
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422908944

Total number of triples: 41.